An investigation on behalf of investors of Hospira, Inc. (NYSE:HSP) in connection with the proposed takeover was announced and NYSE:HSP stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 02/09/2015 --An investigation on behalf of investors, who currently hold shares of Hospira, Inc. (NYSE:HSP), was announced concerning whether the takeover of Hospira, Inc. by Pfizer Inc is unfair to NYSE:HSP stockholders.

Investors who purchased shares of Hospira, Inc. (NYSE:HSP) and currently hold any of those NYSE:HSP shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Hospira, Inc. breached their fiduciary duties owed to NYSE:HSP investors in connection with the proposed acquisition.

On February 5, 2015, Pfizer Inc. (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) announced that they have entered into a merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.

However, the investigation concerns whether the offer is unfair to NYSE:HSP stockholders. More specifically, the investigation concerns whether the Hospira Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Shares of Hospira, Inc. (NYSE:HSP) closed on February 5, 2015, at $87.64 per share.

Those who are current investors in Hospira, Inc. (NYSE:HSP) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com